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Right ventricular outfl ow tract 
revalvulation using the Melody 
Valve: The next frontier
in terms of years of freedom from re-operation. Freedom from 
re-operation varies (see Table I) with rates of 97% at one year to, 
on average, 70% and 31% after 10 and 15 years respectively.(1-3) 
Low body weight, younger age at insertion, small size grafts and 
longer cross-clamping times are factors associated with early graft 
failure.(1,4) It has been estimated that these patients may require up 
to 5 conduit revisions over a lifetime. 
Multiple conduit revisions in these patients often result in prolonged 
hospital stays, increased morbidity and mortality due to the fact 
that difficulty of surgery increases with every re-operation. This may 
result in a considerable increase in medical costs and a negative 
impact on quality of life. Nevertheless, surgery has good long term 
survival and should be considered as the gold standard of treatment. 
PERCUTANEOUS RVOT REVALVULATION
Until recently, surgery was the only option for managing RVOT 
dysfunction. The first percutaneous pulmonary valve was implanted 
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Various congenital heart lesions with anatomical abnormalities 
involving the right ventricular outflow tract (RVOT) will require 
surgical repair early in childhood. Classical lesions include tetralogy 
of Fallot, pulmonary atresia and truncus arteriosus. A significant 
number of these will, over time, develop additional problems of the 
RVOT which will need to be addressed in order to prevent right 
ventricular dysfunction. 
SURGICAL REVALVULATION 
Surgery has been the preferred method of establishing RVOT 
revalvulation. It has traditionally been reserved for children older 
than 3 years. Surgical revalvulation consists of the implantation of 
allo- or xenografts. Pulmonary homografts are generally preferred, 
but other valves e.g. Contegra® or prosthetic conduits are also 
being used. Due to improvements in surgical techniques, mortality 
for re-operation has declined and is now in the region of 3.7%. 
However, failure of the conduit eventually occurs because of 
limited longevity. Conduit degeneration is observed in more than 
75% of homografts over time. Lifespan of conduits are measured 
Congenital heart lesions with abnormal right ventricular 
outfl ow tract anatomy will require early surgical intervention. 
Re-intervention rates in these patients are high due to 
homograft degeneration. Until recently, surgery was the only 
treatment option for right ventricular outfl ow tract dys-
function. Percutaneous pulmonary valve implantation has 
been introduced as a new therapeutic alternative to prolong 
conduit life span and to reduce surgical re-intervention 
rates. Short- and mid-term results have been favourable 
and showed that it is a safe and effective therapy. These 
are reviewed with emphasis on the Melody valve.  
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TABLE 1: Freedom from surgical re-intervention
 Freedom from re-intervention (%)
Series Number(n) Published 1y 5y 10y 15y
Kim(1) 112 2011 97 77 35 
Dearnari(3) 1095 2003    55 32


















in the year 2000 by Professor Philippe Bonhoeffer.(5) This work 
resulted in the development of the Melody® valve (Medtronic, 
Minneapolis, MN, USA), which is a dedicated percutaneous pul-
monary valve which is now commercially available. The Edwards 
SAPIEN transcatheter heart valve (Edwards Lifesciences, Inc., Irvine, 
California) was initially developed for patients with severe aortic 
stenosis. This valve has since been used and adapted for RVOT 
dysfunction in the pulmonary position.(6) The current Melody® 
valve is available in 18 - 22mm diameters and the Edwards SAPIEN 
valve in 23 and 26mm sizes. 
CURRENT INDICATIONS FOR PERCUTANEOUS 
PULMONARY VALVE IMPLANTATION 
Only patients meeting indications for surgical re-intervention qualify 
for consideration of valve implantation. Clinical and morphological 
indications and contraindications for Melody® valve implantation 
can be viewed in Table 2.
DIAGNOSTIC EVALUATION
Patients with right ventricle to pulmonary artery (RV-PA) conduit 
dysfunction need to be evaluated for possible percutaneous pul-
monary valve implantation (PPVI). ECG holter is performed to 
identify possible arrhythmias and for calculation of QRS intervals. 
Objective functional assessment to determine exercise capacity 
can be done by measuring the peak oxygen uptake (VO2max) 
and anaerobic threshold derived from respiratory gas analysis 
during maximal exercise testing.(7-9) Transthoracic echocardiography 
is used to determine right ventricular pressure load, size and 
categorical assessment of pulmonary regurgitation. However, echo-
cardiographic right ventricular functional assessment does not 
correlate well with cardiac magnetic resonance imaging (MRI).(10,11) 
Pulmonary regurgitation severity should be assessed and classified. 
RVOT anatomy, RV-PA mean gradients, mitral- and tricuspid regur-
gitant jets can yield valuable information.(8-11)
High resolution computed tomography (CT) angiography of the 
RVOT gives important information regarding RVOT anatomy and 
the spatial relationship to the coronary arteries.(8) CT angiography 
does, however, have added radiation exposure compared to 
MRI. Cardiac MRI gathers valuable information regarding ventricle 
mass, function and volumes and is currently the preferred 
investigation.(7,8,13)
TECHNICAL ASPECTS OF RVOT REVALVULATION 
BY MEANS OF THE MELODY® VALVE
The Melody® valve consists of a segment of modified-bovine jugular 
vein sutured into a platinum iridium stent of 34mm in length. The 
valve can be crimped down to 6mm and re-expanded from a mini-
mum of 18mm to a maximum of 22mm (Figure 1A).
Delivery system
The Ensemble transcatheter delivery system was designed for 
percutaneous Melody® valve implantation and consists of a balloon-
in-balloon structure with a retractable sheath for valve covering 
post crimping. The system is 100cm in length and has an outer 
diameter of 22Fr size (Figure 1B).
TABLE 2: Melody® valve: Indications and contraindications
Inclusion criteria
Weight ≥30kg
Conduit size ≥16mm 
Dysfunctional RVOT conduits 
with clinical indication for 
reintervention, and either :
Regurgitantion: ≥ moderate
regurgitation or
Stenosis: mean RVOT gradient 
≥35mmHg
Exclusion criteria
Unfavorable coronary artery anatomy
Central vein obstruction 
Venous anatomy cannot 
accommodate a 22-Fr size introducer
Pregnancy
Active infection
FIGURE 1: Melody® valve and Ensemble delivery catheter
(A) The valve is partially crimped over the balloon portion of the 





Central venous accesses, preferably femoral access is obtained. 
Right and left heart catheterisation with a full set of hemodynamic 
calculations is performed. Patients meeting the inclusion criteria 
will then undergo simultaneous coronary angiography and inflation 
of a low pressure balloon in RVOT to exclude coronary artery 
compression (Figure 2).(8,10) Absence of ischemic ECG changes in 
combination with normal coronary angiography information will be 
reassuring for continuation of the procedure.
Use of a stiff guidewire [Meier (Boston Scientific, Natick, MA, USA), 
Lunderquist™ Extra Stiff (COOK Medical., Bloomington, USA) and 
Amplatz Ultra Stiff (COOK Medical, Bloomington, USA)] in a safe 
and stable position is of critical importance and will prevent serious 
complications such as pulmonary artery perforations. 
Preparing the “landing zone” for Melody® valve implantation is a 
crucial step in the procedure. This is done by predilating and pre-
stenting the RVOT. High pressure balloons [Mullins-X Ultra high 
pressure (NuMED, Hopkinton, NY, USA) or Bard Atlas® PTA 
balloons (Bard Peripheral Vascular, Tempe, AZ, USA)] and stents 
with a high radial strength are preferred [Andra stent (Andramed 
GmbH, Reutlingen, Germany), Intrastent Max LD (ev3 Endo-
vascular, Plymouth, USA)]. The decision to use a covered or bare 
RV OUTFLOW TRACT REVALVULATION
FIGURE 2: Demonstration of coronary artery proximity
Simultaneous coronary angiogram with infl ation of a low pressure 
balloon in the RVOT demonstrates that the coronary arteries are 
not in danger of occlusion.  
FIGURE 4: Post valve implantation angiogram
Angiogram in pulmonary artery distal to newly implanted valve 
demonstrates no pulmonary regurgitation. 
FIGURE 3: Melody® valve expanded
 The Melody® valve delivered into the prestented RVOT. Note the 


















metal stent for pre-stenting will be influenced by the risks of 
homograft rupture. Most operators would nowadays prefer to 
use a long covered stent (≥45mm) in a homograft since calci-
fied, crimped homografts fracture if dilated. In these patients 
flaring proximal and distal ends to appose tightly to the surrounding 
tissues at the proximal and distal anastomsis would be important. 
It is essential to create a stable Melody® landing site and any recoil 
during pre-stenting should lead to additional stenting. It is important 
to note that any residual RVOT gradient >15mmHg should not 
be accepted prior to valve deployment.
Once RVOT rehabilitation has been performed, the Melody® valve 
is delivered in an appropriate position (Figure 3). Repeat hemo-
dynamic assessment and angiography are performed to evaluate 
the result (Figure 4). Residual gradients can be treated with high 
pressure balloon dilatation after valve implantation. Cardiothoracic 
backup is desirable during the procedure.
OUTCOMES OF PERCUTANEOUS PULMONARY 
VALVE IMPLANTATION 
More than 3 000 valves have been implanted worldwide and overall 
mortality is very low (0% - 1%).(7,10,12,14-17) Procedural success for 
attempted percutaneous valve implantation is excellent. The most 
common exclusion factor has been the risk of coronary compres-
sion. Significant reduction in outflow tract gradient and/or abolish-
ment of pulmonary regurgitation was observed in all cases. Right 
ventricular volumes also improved markedly. 
Major procedural complications included dislodgement of the valve, 
coronary compression, rupture of homograft and haemothorax 
due to pulmonary artery perforations.(7,13-18) Dislodgement of the 
device occurred mostly during the initial development phase and 
could be related to operator inexperience as well as the early 
learning curve. It is now extremely rare, especially with pre-stenting. 
Coronary compression was responsible for virtually all deaths 
resulting from percutaneous revalvulation. Since this is a potentially 
avoidable complication, pre-selection with sophisticated imaging 
modalities as mentioned have become essential. Rupture of homo-
graft conduits is a rare, but ever present risk. Therefore, making 
routine use of a covered stent or at least having one of these 
available during the procedure is essential. The pulmonary arteries 
may be perforated by the very stiff guidewires employed to deliver 
the valve. In the worldwide experience, some resolved spon-
taneously, could be treated by implanting a covered stent to seal off 
the perforation or required a thoracotomy. Overall, early com-
plications were rare during percutaneous procedures, occurring in 
less than 8.5% of implantations.(8,16,17) This compares favorably to 
surgical series where early complications have been described in up 
to 9.6% of patients.(18) 
Follow-up results for outcome are now short to mid-term. The 
most common complication has been stent fractures which 
occurred in 5% to 30% of cases.(14,15,19) Although the vast majority 
of stent fractures remain asymptomatic, it may lead to the develop- 
ment of outflow tract gradients. However, this can easily be treated 
with the implantation of another percutaneous valve. This problem 
is likely to decrease due to the current practice of routine right 
ventricular outflow tract pre-stenting. Although extremely rare, 
endocarditis is a vexing problem and the most common reason for 
valve explantation.(20)
Freedom from valve dysfunction or re-operation ranged from 
95 - 100% at one year to 70% at seventy months during follow-
up.(8,14,15) These results provide evidence that the initial aim of 
prolonging the life-span of surgically placed right ventricular outflow 
tract conduits can be successfully achieved by the implantation of 
a percutaneous valve.
Cost analyses have been favourable. Although the valve itself is 
expensive, the low morbidity and short hospital stay makes total 
cost comparable to that of surgery.(21) It should be pointed out 
that cost comparisons for South Africa are currently not available. 
The main benefits of percutaneous pulmonary valve implantations 
are the low risks, short hospital stays, delay in the need for surgery 
and improvement in quality of life. 
TIMING OF RIGHT VENTRICLE OUTFLOW TRACT 
REVALVULATION:  THE CONTROVERSY
Right ventricular outflow tract dysfunction is one of the most 
common killers in congenital heart diseases. Although the indica-
tions for intervention in stenosis are clearly defined, the same 
cannot be said for pulmonary valve regurgitation. As a matter of 
fact, it is a well-established fact that some patients with pulmo-
nary regurgitation and dilated right ventricles show little improve-
ment after right ventricular outflow tract revalvulation. Optimal 
timing of surgery in this subgroup of patients is not clear and 
remains controversial. The reason for this is that we currently do 
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not know how much overload a right ventricle can tolerate before 
irreversible damage sets in. 
Patients with pulmonary regurgitation present with dilated right 
ventricles because of the increased volume loads on the ventricles. 
Studies in post-operative patients with tetralogy of Fallot and 
pulmonary regurgitation have shown abnormal right ventricular 
deformation indices despite normal global right ventricular func-
tion.(22) Right ventricular ejection fractions assessed by cardiac MRI 
were normal, signifying that right ventricle systolic function para-
meters only become abnormal late in RVOT dysfunction and long 
after dysfunction at cellular level was present. In another study in 
elite cyclists, a disproportionate incidence of ventricular tachy-
cardia and sudden death was observed.(23) Dilation of their right 
ventricles was demonstrated and ascribed to the large volume 
loads on the heart during frequent peak exercise. This caused right 
heart injury resulting in electrical dysfunction as the presenting 
symptom. It is important to take note of the fact that the 
dysrrhytmias in all the athletes occurred before measurable right 
ventricular dysfunction became apparent. 
Compare this to patients with right ventricular outflow tract dys-
function – we know that it leads to right heart dilation and that a 
significant number die unexpectedly due to arrhythmias. Further-
more, these dilated right ventricles have normal or near normal 
function on MRI. All these findings suggest that electrical and cellu-
lar level dysfunction set in long before global mechanical dysfunc-
tion becomes apparent. If we allow too much time to pass before 
revalvulation, irreparable damage may occur to the right ventricle 
explaining the poor results of revalvulation in some patients. In the 
past, physicians tended to wait as long as possible before inter-
vening due to the risks and morbidity associated with surgery. In 
this new era of percutaneous valves, one may thus consider 
revalvulation at an earlier age in order to preserve right ventricular 
mechanics. As a result, some physicians advocate intervention in 
these patients before they become symptomatic. However, at 
present we still do not have the ability to accurately measure when 
it is time to intervene in asymptomatic patients and the timing of 
intervention is bound to remain controversial until we can scienti-
fically define measureable right ventricle parameters to guide the 
decision. 
FUTURE DEVELOPMENTS
New developments consist of mounting valves on stronger stents 
and a new version of the Melody® valve will soon become available. 
Also, valves are being developed for larger outflow tracts which 
cannot be treated with the current valve sizes available. This has 
been a limiting factor in some patients, especially patients with 
dilated outflow tracts. Recent studies have also shown that the 
valve can be implanted in selected cases in younger patients 
(<20kg) and has even been used during hybrid procedures to 
avoid cardiac bypass.(24) Surgeons are also adapting techniques at 
initial procedures to construct conduit angles amenable to trans-
catheter intervention and at a safe distance from the coronary 
arteries. 
CONCLUSION
Percutaneous pulmonary valves are a safe and effective therapy for 
revalvulation of the right ventricular outflow tract. The stented 
valves can be implanted with a high success rate as well as low 
morbidity and mortality.  Results have proven that percutaneous 
pulmonary valves extend the lifespan of conduits. It is important 
to realise that percutaneous revalvulation is complimentary to 
surgery and not in competition with surgical revalvulation. The 
availability of percutaneous valves may change the way in which we 
approach right ventricular revalvulation in the future, but remains 
controversial at present for certain indications.
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